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Abstract
Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers
predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly
diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has
been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free
after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with
11.8% for those progressing within the first 5 years. Hemoglobin (Hb) ≥ 12 g/dl (OR 2.74, p= 0.001) and MGUS-like
profile (OR 4.18, p= 0.005) were the two baseline variables associated with long-term disease-free survival. Upon
including depth of response (and MRD), Hb ≥ 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their
predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the
probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this
endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-
treatment biomarkers helpful in predicting the likelihood of disease control at 5 years.
Introduction
Treatment of multiple myeloma (MM) has significantly
improved in the last decade but the outcome remain
significantly poorer in elderly patients1. Thus, while
approximately 34–60% of transplant-eligible cases remain
progression free at 5 years2–4 and this has resulted in
unprecedent rates (10–40%) of 10-year overall survival
(OS)2–4; the percentage of elderly patients reaching dis-
ease control at 5 years and the characteristics of such
patients is less well established. Moreover, in the non-
transplant-eligible population, definition of long-term
disease control could be different, since patients that are
free from relapse beyond 5 years, could eventually die for
reasons other than progressive disease. Thus, achieving
disease control beyond 5 years would be a most relevant
endpoint, since elderly patients usually have fewer options
for subsequent lines of therapy, and a prolonged first
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response will translate not only into a longer survival but
also in improved quality of life.
Several studies have searched for relevant prognostic
factors associated with prolonged survival in elderly MM.
Thus, in addition to a fit status, according to geriatric
assessment5, and absence of high-risk cytogenetic
abnormalities (HR CAs)6, both the International Staging
System (ISS) and the Revised-ISS (R-ISS)7,8 clearly iden-
tified that ISS 1 and R-ISS 1 patients enjoy a significantly
longer progression-free survival (PFS) and OS. Additional
conventional factors such as normal hemoglobin (Hb),
creatinine, and beta-2-microglobulin (B2M) levels, age
below 80 years and normal lactate dehydrogenase (LDH)
levels, as well as, low percentage of S-phase bone marrow
(BM) plasma cells (PCs), have been identified as pre-
dictors for longer PFS and OS9–11. Nevertheless, none of
these studies have specifically focused on the identifica-
tion of the characteristics of the patients' cohort that
achieve a long-term disease control (PFS > 5 years).
Depth of response is also associated with prolonged
survival in elderly patients. Thus, complete response
(CR) defined by conventional criteria translates into
longer PFS and OS12–14. More recently, it has been
shown that the achievement of sustained minimal resi-
dual disease negativity clearly predict for a longer PFS
and OS in non-transplant candidate patients15. How-
ever, there is a small subset of MM patients that despite
persistence of the disease enjoy long-term disease con-
trol, underlying the need of new tools to identify these
long-term survivors.
Interestingly, it has been reported that patients with a
previous diagnosis of monoclonal gammopathy of
unknown significance (MGUS) or smoldering MM
(SMM) have a more prolonged survival16. However,
although it is well known that all MM evolve from a
prior MGUS, in most patients presenting with active
disease no information on a previous MGUS-status is
available. Noteworthy, both the Arkansas17 and the
Spanish groups18 have reported, by using gene expres-
sion profiling (GEP) and multiparameter flow cytometry
(MFC) techniques, respectively, that an MGUS sig-
nature, associated with low-risk features and superior
survival, can be identified in a fraction of patients with
active MM.
Here, we evaluated a large series of 498 transplant-
ineligible MM patients enrolled in two consecutive
Spanish clinical trials, treated with first-generation novel
agent-based combinations and with mature follow-up.
Our aims were to (i) determine the percentage of elderly
patients with disease control at 5 years after treatment
initiation, (ii) analyze whether this translates into a sub-
stantial benefit in OS, and (iii) define an optimal set of
biomarkers to estimate the odds of achieving disease
control at 5 years.
Patients and methods
Study design
Four hundred ninety-eight newly diagnosed elderly and
symptomatic MM patients (aged 65 years or older) were
included in two prospective Spanish trials: GEM2005-
MAS65 and GEM2010MAS6519–22. Patients with a
follow-up shorter than 5 years (n= 22) or who died
without progression (n= 41) were censored from the
analysis and, accordingly, 435 patients were evaluated in
this post-hoc study. All patients were diagnosed according
to the IMWG criteria23. Data cut-off was 20 February
2018. All patients provided written informed consent
before screening. Data were monitored by an external
contract research organization and centrally re-assessed.
Median follow-up was 92.6 months (range:
0.3–132.9 months) and 61.7 (range: 1.6–81.1 months) for
the GEM2005MAS65 and the GEM2010MAS65 studies,
respectively. The endpoint of this study was defined as
time to progression at 5 years or longer since diagnosis, in
patients with a follow-up of at least 5 years.
The GEM05MAS65 trial included 259 patients rando-
mized to receive upfront induction treatment with either
bortezomib, melphalan, and prednisone (VMP), or bor-
tezomib, thalidomide, and prednisone (VTP)16. VMP
induction therapy consisted of six cycles: one cycle of
intravenous bortezomib given twice per week for 6 weeks
(1.3 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32), plus
oral melphalan 9mg/m2 and prednisone 60mg/m2 on
days 1–4, followed by five cycles of bortezomib once per
week for 5 weeks (1.3 mg/m2 on days 1, 8, 15, and 22) plus
the same doses of melphalan and prednisone. VTP
induction therapy consisted of the same schedule of
bortezomib and prednisone plus oral, continuous, thali-
domide at a dose of 100 mg per day instead of melphalan.
Patients from each arm completing the six induction
cycles were then randomly assigned to maintenance
therapy with either bortezomib and thalidomide (VT) or
bortezomib and prednisone (VP). Maintenance consisted
of one conventional cycle of bortezomib (1.3 mg/m2 on
days 1, 4, 8, and 11) every 3 months, plus either oral
prednisone (50 mg every other day) or oral thalidomide
(50 mg per day), for up to 3 years.
In the GEM010MAS65, 239 patients were randomly
assigned 1:1 to receive both VMP and lenalidomide in
combination with low-dose dexamethasone (Rd) in a
sequential or alternating manner, for 18 cycles17. VMP
therapy comprised nine cycles: one 6-week cycle of IV
bortezomib using a conventional twice-weekly schedule
(1.3 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32), plus
oral melphalan (9 mg/m2) and oral prednisone (60 mg/
m2) on days 1–4, followed by eight 4-week cycles of once-
weekly IV bortezomib (1.3 mg/m2 on days 1, 8, 15, and 22)
plus the same doses of melphalan and prednisone. Rd
treatment consisted of nine cycles of oral lenalidomide
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25mg daily on days 1–21 of each 28-day cycle plus oral
dexamethasone 40 mg weekly, on days 1, 8, 15, and 22.
The following characteristics, documented at diagnosis,
were analyzed: age, gender, Hb, serum creatinine levels,
B2M, albumin, PC infiltration, LDH, type of monoclonal
component, presence of urine light chains, extramedullary
disease, clinical staging according to the ISS and R-ISS,
plus chromosomal abnormalities defining high-risk
patients: t(4;14) and/or t(14;16) and/or del(17p).
In addition, an immunophenotypic algorithm to deter-
mine if patients had MGUS-like vs MM-like profiles was
used by comparing the relative frequency of BM PCs plus
the percentage of clonal and normal PCs within the whole
BM PC compartment for each patient, plotted against a
database containing information on the same three
parameters from a total of 1774 patients, including 497
MGUS and 1277 newly diagnosed MM enrolled in the
GEM2000 (N= 486) plus GEM2005MENOS65 (N= 330)
protocols for transplant-eligible cases, and the
GEM2005MENOS65 (N= 239) plus GEM2010MAS65
(N= 222) protocols for transplant-ineligible patients.
Based on those three parameters and the automatic
population separator (APS) representation of the Infinicyt
software (Cytognos, Salamanca, Spain), two reference
groups corresponding to MGUS and MM emerged; each
patient falling into the MGUS reference being classified as
MGUS-like (Supplementary Figure 1)18.
Fluorescence in situ hybridization (FISH) on CD138-
purified PCs and immunophenotyping were performed
centrally at diagnosis following standard procedures6.
Responses were evaluated according to the European
Group for Blood and Marrow Transplantation24 and
IMWG25 criteria.
Statistical analysis
The endpoint of this study was defined as time to
progression at 5 years or longer since diagnosis, in
patients with a follow-up of at least 5 years.
The baseline characteristics of the patients are pre-
sented as mean and standard deviation (SD) for con-
tinuous variables and as proportions for categorical
variables. Univariate analysis was performed using the
chi-squared or Fisher’s exact test, as appropriate, for
independent variables. Multivariate analysis was per-
formed using a forward-stepwise model. Variable selec-
tion to be tested in the multivariate analysis was carried
out using an automated selection method (forward-step-
wise). Two significance levels were specified in the
forward-stepwise procedure: 10% for predictor addition to
the model, and 20% for predictor removal from the model.
A first model including all the baseline variables was
performed and a second model including depth of
response based on conventional and minimal residual
disease evaluation was conducted using the same criteria.
In both models, the R-ISS was included instead of ISS,
LDH, and HR CAs in order to avoid redundancy. A
landmark analysis at 6 and 12 months has been performed
including all patients. Crude survival analysis was assessed
using log-rank test. Kaplan–Meier survival analysis was
carried out for each group category. All statistical analyses
were carried out using Stata 12.1.
Results
The median PFS for the whole population included in
the GEM05MAS65 and GEM2010MAS65 (n= 498) was
31.4 month (95% confidence inerval (CI), 28.28–34.36),
being 28.3 months (95% CI, 24.8–32.9) and 34.3 months
(95% CI, 29.6–39.1) in each trial, respectively. The median
OS was 57.3 months (95% CI, 49.1–65.4), being
51.6 months (95% CI, 42.9–61.1) and 68.2 months (95%
CI, 49.1–NR) for patients included in the GEM05MAS65
and GEM2010MAS65 trials, respectively.
Four hundred thirty-five newly diagnosed transplant-
ineligible MM patients were analyzed in this post-hoc
study. Eighty-one out of 435 patients (18.6%) were alive
and without disease progression during the first 5 years of
initiating treatment and this group of patients has been
identified as the long-term disease-free survivor group.
The remaining 354 patients have progressed in the first 5
years after the diagnosis. The proportion of patients alive
at 10 years in the long-term disease-free survivor group
was 60.8% (95% CI, 35.4%–78.8%) as compared
with 11.8% (95% CI, 5.9%–19.8%) (p < 0.001), respectively
(Fig. 1).
Results of the univariate analyses are summarized in
Table 1. Baseline variables significantly associated with
long-term PFS were, ISS 1 (35% vs 22.3%; p= 0.036), R-
ISS 1 (30% vs 16.6%, p= 0.002), Hb ≥ 12 g/dl (34.6% vs
17.8%, p= 0.001), normal LDH (97.5% vs 87.6%, p=
0.009), and absence of HR CAs (91% vs 80.9%, p= 0.04).
(HR 0.09; 95% CI  0.05 – 0.16, p=0.000)
Fig. 1 Kaplan–Meier curves of overall survival in long-term
survivor group as compared with the remainder
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Moreover, patients in the long-term disease-free survivor
group presented more frequently an MGUS-like profile
(15.6 % vs 3.7%, p < 0.001). In addition, quality of response
measure by both the proportion of complete remissions
(CRs) (58% vs 33.3%, p= 0.001), and MRD-negative cases
(41.9% vs 9.9%, p < 0.001) were also higher in the long-
term PFS group.
The multivariate logistic regression analysis showed that
the probability of long-term disease control was asso-
ciated with two independent baseline factors (Table 2a):
the presence of an Hb ≥ 12 g/dl (OR 2.74; 95% CI,
1.53–4.89, p= 0.001), and the presence of an MGUS-like
profile in the BM PCs (OR 4.18; 95% CI, 1.5–11.3, p=
0.005). When incorporating depth of response and
patients’ MRD status into the model, three variables were
found to be independently associated with the probability
of 5-year PFS (Table 2b): the presence of an MGUS-like
profile (OR 7.48; 95% CI, 2.46–22.74, p < 0.001); the MRD
negativity (OR 5.18; 95% CI, 2.77–9.69, p < 0.001), and the
Hb ≥ 12 g/dl (OR 2.27; 95% CI, 1.22–4.22, p= 0.009).
Moreover, after performing a landmark analysis at 6 and
12 months including all patients (n= 498), the three
variables significantly associated with long-term survival
remain the same (Hb > 12, MGUS-like profile and MRD
negativity).
Focusing on the 24 patients with an MGUS-like sig-
nature, 50% of these patients displayed a long-term dis-
ease-free survival, as compared with 17.3% of the
remaining MM patients. The proportion of patients alive
at 10 years with an MGUS-like profile was 40.5% (95% CI,
9.4–70.7) as compared with 20.3% (95% CI, 12.7–29.2) in
the MM-like population (p = 0.07). Similarly, for PFS, the
proportion of patients alive and without disease progres-
sion at 10 years in the MGUS-like group was 40.2% (95%
CI, 20.5–59.1) as compared with 5.7% (95% CI, 2.8–10.1)
among the MM-like patients (p = 0.001). Disease
response has been evaluated in 21 out of 24 patients with
MGUS-like profile and 90% of the patients achieved a
favorable response (10 CR and 9 VGPR). No differences in
Table 1 Distribution of the main characteristic between
the long-term survival group and the remainder
population (univariate analysis)
Variable Long-term survival,
n (%)
Remainder, n (%) p-Value
Age n= 81 n= 354 p= n.s.
<75 years 56 (69.1) 224 (63.2)
Gender n= 81 n= 354 p= n.s.
Male 46 (56.8) 178 (50.3)
Protocol n= 81 n= 354 p= n.s.
GEM05MAS65 44 (54.3) 206 (58.2)
GEM2010MAS65 37 (45.7) 148 (41.8)
Durie stage n= 81 n= 352 p= n.s.
I 12 (14.8) 29 (8.2)
II 42 (51.8) 168 (47.8)
III 27 (33.3) 155 (44)
ISS n= 80 n= 350 p= 0.036
ISS 1 28 (35) 78 (22.3)
ISS 2 33 (41.2) 151 (43.1)
ISS 3 19 (23.8) 121 (34.6)
R-ISS n= 80 n= 350 p= 0.002
R-ISS 1 24 (30) 58 (16.6)
R-ISS 2 55 (68.8) 256 (73.1)
R-ISS 3 1 (1.2) 36 (10.3)
Hemoglobin (g/dl) n= 81 n= 354 p= 0.001
Hb ≥ 12 g/dl 28 (34.6) 63 (17.8)
Creatinine (mg/dl) n= 81 n= 354 p= n.s.
Creat < 1.1 54 (66.7) 242 (68.4)
LDH n= 81 n= 348 p= 0.009
Normal 79 (97.5) 305 (87.6)
Cytogenetics n= 75 n= 335 p= 0.04
Standard risk 68 (91) 271 (80.9)
Response n= 81 n= 327 p= 0.001
CR (sCR+ CR IF-) 47 (58) 109 (33.3)
VGPR 27 (33.3) 161 (49.2)
PR 4 (4.9) 45 (13.8)
SD 3 (3.7) 11 (3.4)
PD 0 (0) 1 (0.3)
BM signature n= 77 N= 323 p < 0.001
MGUS-like profile 12 (15.6) 12 (3.7)
MM-like profile 68 (84.4) 311 (96.3)
MRD n= 81 n= 354 p < 0.001
Negative 35 (41.9) 35 (9.9)
n.s. not statistically significant, MRD minimal residual disease, CR complete
response, sCR stringent complete response, CR IF- complete response with
negative immunofixation, VGPR very good partial response, PR partial response,
SD stable disease, PD progressive disease, Hb hemoglobin, Creat creatinine, ISS
International Staging System, R-ISS revised International Staging System, LDH
lactate deshydrogenase
Table 2a Multivariate analysis including baseline
variables
Odds ratio 95% CI p-Value
MGUS-like profile 4.18 1.55–11.26 0.005
Hb ≥ 12 g/dl 2.74 1.53–4.89 0.001
MGUS monoclonal gammopathy of unknown significance, Hb hemoglobin, 95%
CI 95% confidence interval
Table 2b Multivariate analysis including depth of
response measured by complete response and MRD
negativity rates
Odds ratio 95% CI p-Value
MGUS-like profile 7.48 2.46–22.74 0.000
Hb ≥ 12 g/dl 2.27 1.22–4.22 0.009
MRD negativity 5.18 2.77–9.69 0.000
MGUS monoclonal gammopathy of unknown significance, Hb hemoglobin, MRD
negativity minimal residual disease negativity detected by flow cytometry
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outcome were observed between VGPR and CR cases (p-
value for OS 0.78) among the MGUS-like profile patients.
Interestingly, as suggested by the multivariate analysis, the
impact of the MGUS-like signature on long-term survival
is independent on the MRD status, since only 16.7% of
these patients achieved MRD negativity, as compared with
46.15% patients in the long-term survival group with a
MM-like profile (p= 0.057).
Discussion
In the transplant setting, it has been clearly shown that
improving the median PFS beyond 5 years resulted in
median OS of 8–12 years2–4. However, it is not so well
established if disease control at 5 years in elderly MM has
a similar impact in OS. Indeed, in this setting it may be
even more relevant, since many elderly patients will only
receive 2–3 lines of therapy, and accordingly, a prolonged
initial response could translate both in a prolonged sur-
vival, similar to that of elderly healthy individuals, and an
improved quality of life. The definition of long-term dis-
ease control used in the present study (PFS beyond 5
years) is quite challenging since it is equivalent to the
median OS reported in the VISTA26 and FIRST trials27
based on VMP (OS: 56 months) or continuous
Lenalidomide-dexamethasone (OS: 59 months) treat-
ments, respectively. Upon considering VRD as a new
standard of care, the median PFS reported for patients
above the age of 65 (35 months) is clearly inferior to the 5
years here proposed28. Taken together, it should be
assumed that despite substantial improvement in the
treatment of MM, the proportion of elderly patients
achieving long-term disease control (i.e.: > 5 years PFS) is
limited and factors identifying this population upfront are
lacking.
In our series, only 18.6% out of 435 elderly patients
entered in this category, and 61% of them achieved an OS
of more than 10 years, accordingly they will reach a life
expectancy similar to the normal population. As expected,
this patients' cohort is characterized by the presence of
low-risk clinical features (R-ISS 1, normal Hb, and LDH).
The ISS, particularly the revised version (R-ISS), that
include the cytogenetic information, is a powerful tool in
discriminating risk subgroups, but their predictive value
for 5-year disease control is not established. By contrast,
the emergence of normal Hb levels as a strong predictor
of long-term disease control was surprising and could
reflect a lower BM infiltration and potentially a better
tolerance to treatment. But the most relevant biomarker
for predicting long-term disease control upfront was the
presence of an MGUS-like signature defined by auto-
mated MFC and characterized by a low number of bone
BM PCs together with a relative preservation in the per-
centage of normal vs clonal PCs within the whole BM PC
compartment. The favorable outcome of patients with an
MGUS-like profile was first shown by the Arkansas group
using a gene expression signature based on 52 genes17.
From 214 patients with MM, 27% were found to have an
MGUS-like signature, and it was associated with low-risk
clinical and molecular features and superior survival.
Moreover, the MGUS-like signature was also seen in PCs
from 15 of 20 patients surviving >10 years after auto-
transplantation. By using MFC, Paiva et al.18 had shown
that 59 out of 689 transplant candidate MM patients (8%)
displayed an MGUS-like profile. Despite achieving similar
CR rates after high-dose therapy vs other MM patients,
MGUS-like cases had very long time to progression and
OS (~60% at 10 years; p < 0.001). Although, MGUS-like
signature does not necessarily drive a long time to pro-
gression, our data indicate that this biomarker can con-
tribute to identify a subset of symptomatic MM patients
with an excellent outcome, independently of the depth of
response. Overall, these data could also imply that treat-
ing patients before massive disease dissemination and
niche occupancy in BM confers favorable prognosis.
Although the depth of response is not predictable at the
time of diagnosis, it was shown to be a significant pre-
dictive marker of long-term disease control when mea-
sured with conventional methods (CR) or, particularly, by
MFC (MRD negativity). Noteworthy, our study highlights
that the prognostic impact of a MGUS-like signature, is
even more relevant than to achieve MRD negativity for
predicting long-term disease control (HR of 7.09 and 4.87,
respectively). Although MRD is becoming a most valuable
treatment endpoint and a surrogate marker for survival,
the fact that MGUS-like and MRD are independent
confirms that for some patients the achievement of an
MRD-negative status is not imperative for attaining long-
term disease control.
In summary, we identified that the combination of three
biomarkers (normal Hb, MGUS-like signature, and MRD
negativity) can help to define elderly MM patients
achieving long-term disease control. Although these
findings will be validated in our next GEM2017FIT trial
for elderly newly diagnosed MM patients, our results
show that the presence of a MGUS-like signature in the
BM at diagnoses is the most powerful predictor for long-
term disease-free survival, becoming an important prog-
nostic biomarker.
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